Following the same conclusion reached by the Kyoto Prefectural University of Medicine and Jikei University School of Medicine, the Shiga University of Medical Science reported Thursday a discovery of manipulated data on a clinical research made on a drug developed by Novartis Pharma KK. The Otsu-based medical school claims that there has been a discrepancy on the clinical report released by the pharmaceutical company.
An in-house committee at the Shiga University of Medical Science found problems on the claims for Novartis’ anti-hypertensive drug, Valsartan. Using the brand name of Diovan, the drug is expected to lower blood pressure. But the medical school from Shiga Prefecture doubts the integrity of the result of the study done on the medicine. The finding is not something new as two other medical schools also had the same conclusion when they conducted their respective investigations.
Back in July, the Kyoto Prefectural University of Medicine was first to disclose its suspicion of possible data manipulation on the research result for Diovan. Though it may be an effective anti-hypertensive drug, its claim to be better or more effective compared to other drugs of the same kind is questionable. On the same month, Minato-based Jikei University School of Medicine also claimed that the research result has been manipulated, adding that one of Novartis’ clinical research participants is actually employed by the Swiss company.
As for Shiga University of Medical Science, 10.1 percent of patient data from the 2007 report showed discrepancies between the original clinical records and the report released on the same year. The medical school’s conclusion was drawn from its independent study on 150 patients diagnosed with hypertension. The report covered the research made beginning 2003 until 2006. Besides the three universities, two other medical schools – Chiba University and Nagoya University – have also made studies on Diovan.
[via The Mainichi]